Amlodipine And Olmesartan Medoxomil Tablet
Product Images NDC 67877-500

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Olmesartan Medoxomil (NDC 67877-500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aml-olm-1 (Aml Olm 1)

A line graph depicting the relationship between baseline systolic blood pressure (SBP) and the percentage of subjects achieving SBP less than 140 mmHg. Four groups are represented: Placebo, Amlodipine 10 mg, Olmesartan Medoxomil 40 mg, and Amlodipine plus Olmesartan Medoxomil 10/40 mg. The graph shows that the combined treatment group achieves the highest percentage of subjects with SBP below 140 mmHg across the baseline SBP range.*

FDA Label Image

Aml-olm-2 (Aml Olm 2)

A line graph showing the percentage of patients with diastolic blood pressure (DBP) below 90 mm Hg plotted against baseline DBP values from 95 to 110 mm Hg. The graph compares the effects of placebo, amlodipine 10 mg, olmesartan medoxomil 40 mg, and a combination of amlodipine 10 mg with olmesartan medoxomil 40 mg on DBP control.*

FDA Label Image

Aml-olm-3 (Aml Olm 3)

A line graph depicting the relationship between baseline systolic blood pressure (SBP) in mmHg (x-axis) and the percentage of subjects with SBP less than 130 mmHg (y-axis). Four groups are compared: Placebo, Amlodipine 10 mg (AML 10 mg), Olmesartan Medoxomil 40 mg (OM 40 mg), and a combination of Amlodipine and Olmesartan Medoxomil 10/40 mg (AML+OM 10/40 mg), with the combination group showing the highest percentage achieving target SBP.*

FDA Label Image

Aml-olm-4 (Aml Olm 4)

A line graph comparing the effects of placebo, amlodipine 10 mg, olmesartan medoxomil 40 mg, and their combination (amlodipine plus olmesartan 10/40 mg) on diastolic blood pressure (DBP). The x-axis shows baseline DBP (mmHg) ranging from 95 to 110 mmHg, and the y-axis shows change in DBP from baseline (Δ DBP, mmHg) down to -80 mmHg. The combination treatment shows the greatest reduction in DBP across the baseline range compared to individual treatments and placebo.*

FDA Label Image

Aml Olm 10 20 90

Label for Amlodipine and Olmesartan Medoxomil Tablets 10 mg/20 mg, oral tablet form. The label indicates prescription use only, contains 90 tablets per bottle, and is distributed by Ascend Laboratories, LLC. It includes storage instructions and manufacturing details by Alkem Laboratories Ltd., India.*

FDA Label Image

Aml Olm 10 40 30

Label for Amlodipine and Olmesartan Medoxomil Tablets, 10 mg / 40 mg, oral tablets in a bottle of 30 count. The label shows the active ingredients with equivalency for amlodipine besylate and olmesartan medoxomil, storage instructions, manufacturer Alkem Laboratories, Ltd., India, and distributor Ascend Laboratories, LLC, Parsippany, NJ. The label includes NDC 67877-502-30 and Ascend Laboratories logo.*

FDA Label Image

Aml Olm 5 20 30

Amlodipine and Olmesartan Medoxomil Tablets label showing strength of 5 mg/20 mg. The label indicates 30 tablets per container, with manufacturer Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC. It includes dosage and use instructions, storage conditions, and a barcode. The label is predominantly white with purple accents and displays the Ascend Laboratories logo.*

FDA Label Image

Aml Olm 5 40 90

Amlodipine and Olmesartan Medoxomil Tablets 5 mg/40 mg oral tablet label. The label includes active ingredient information, storage instructions, manufacturer (Alkem Laboratories, Ltd., India), distributor (Ascend Laboratories, LLC), and package size of 90 tablets. It features the Ascend logo and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.